CL-67.772
Amoxapine
CAS: 14028-44-5
Molecular Formula: C17H16ClN3O
CL-67.772 - Names and Identifiers
| Name | Amoxapine |
| Synonyms | amoxan Asendis Defanyl Asendin Ascendin CL 67772 Amoxepine Amoxapine CL-67.772 237-867-1 2-chloro-11-piperazin-1-yldibenzo[b,f][1,4]oxazepine 2-chloro-11-pipérazin-1-yldibenzo[b,f][1,4]oxazépine 2-Chloro-11-(1-piperazinyl)dibenzo[b,f][1,4]oxazepine 2-Chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine Dibenz(b,f)(1,4)oxazepine, 2-chloro-11-(1-piperazinyl)- dibenz[b,f][1,4]oxazepine, 2-chloro-11-(1-piperazinyl)- |
| CAS | 14028-44-5 |
| EINECS | 237-867-1 |
| InChI | InChI=1/C17H16ClN3O/c18-12-5-6-15-13(11-12)17(21-9-7-19-8-10-21)20-14-3-1-2-4-16(14)22-15/h1-6,11,19H,7-10H2 |
CL-67.772 - Physico-chemical Properties
| Molecular Formula | C17H16ClN3O |
| Molar Mass | 313.78 |
| Density | 1.2613 (rough estimate) |
| Melting Point | 175-1760C |
| Boling Point | 469.9±55.0 °C(Predicted) |
| Flash Point | 9℃ |
| Solubility | methanol: soluble |
| Vapor Presure | 5.32E-09mmHg at 25°C |
| Appearance | White solid |
| Color | Crystals from benzene/pet ether |
| Merck | 14,576 |
| pKa | pKa 7.6 (Uncertain) |
| Storage Condition | Keep in dark place,Inert atmosphere,Room temperature |
| Refractive Index | 1.5800 (estimate) |
| Use | Used as an antidepressant |
CL-67.772 - Risk and Safety
| Hazard Symbols | Xn - Harmful |
| Risk Codes | 22 - Harmful if swallowed |
| Safety Description | 36 - Wear suitable protective clothing. |
| UN IDs | 3249 |
| WGK Germany | 3 |
| RTECS | HQ4025500 |
| HS Code | 2934990002 |
| Hazard Class | 6.1(b) |
| Packing Group | III |
| Toxicity | LD50 in mice (mg/kg): 122 i.p.; 112 orally (Howell, 1972) |
CL-67.772 - Reference Information
| NIST chemical information | Information provided by: webbook.nist.gov (external link) |
| pharmacological effects | amoxapine is a tricyclic antidepressant. Compared with imipramine, it has similar antidepressant effect, but it has fast onset, low toxicity to the heart, and weak anticholinergic and sedative effects. This product can inhibit the reuptake of norepinephrine by the presynaptic membrane in the brain (with little effect on the reuptake of serotonin), resulting in strong antidepressant and mental excitement. |
| pharmacokinetics | absorption is rapid and complete after oral administration, reaching the peak blood drug concentration in 1~2 hours, and the concentration in tissues is 10 times higher than that in plasma. Metabolism by the liver, the metabolites 7-hydroxyamoxapine and 8-hydroxyamoxapine still have antidepressant activity. Most of it is excreted by the kidneys. It is suitable for the treatment of various types of depression, but it is less effective for psychotic depression. |
| indication | is suitable for the treatment of various types of depression. it is also effective for patients with endogenous depression who are ineffective in the treatment of other antidepressants, but it has poor curative effect on psychotic depression. |
| adverse reactions | 1. common digestive tract reactions, such as dry mouth and constipation. 2. Occasionally dizziness, drowsiness and muscle tremor. 3. Extrapyramidal symptoms can be seen during long-term large-scale application. 4. Rare mild increase in heart rate, orthostatic hypotension, chorea, eye movement crisis. |
| drug interaction | 1. combined with antihistamines, it can strengthen anticholinergic effect. 2. Cimetidine, fluoxetine, paroxetine, quinidine and sertraline can slow down the metabolism of this product and cause poisoning of this product. 3. Combined with clonidine and reserpine, the antihypertensive effect of the latter can be weakened. 4. Combined with thyroid hormone, can increase the risk of arrhythmia. 5. When combined with perphenazine, fluphenazine, flupentixol, haloperidol and other drugs, they can affect each other's metabolism, resulting in increased blood drug concentration and increased adverse reactions. 6. Combined with cisapride, moxifloxacin and other drugs, it can cause toxic damage to the heart due to the additive effect of QT interval prolongation. 7. Combined with carbamazepine, the blood concentration of this product decreases, the blood concentration of carbamazepine increases, and the toxicity increases. 8. Combined with anticoagulants such as dicoumarin and warfarin, the latter has reduced metabolism, increased absorption and increased bleeding risk. 9. When combined with salmeterol, it can increase cardiovascular excitability. 10. Combined with estrogen or estrogen-containing contraceptives, it can increase the adverse reactions of this product. |
| use | antidepressants. Used as an antidepressant |
| Production method | The reaction of ethyl chloroformate and o-(p-chlorophenoxy) aniline hydrochloride to produce o-(p-chlorophenoxy) phenyl ethyl carbamate, and then make it react with N-ethyl piperazine to generate 4-[[o-(p-chlorophenoxy) phenyl] carbamoyl]-1-zine piperoxycarboxylate, the piperazine carboxylate, phosphorus pentoxide and phosphorus oxychloride are heated and refluxed together to obtain chloropine. |
| category | toxic substances |
| toxicity classification | highly toxic |
| acute toxicity | oral-rat LD50: 313 mg/kg; Oral-mouse LD50: 122 mg/kg |
| flammability hazard characteristics | flammability; heating produces toxic nitrogen oxides and chloride smoke |
| storage and transportation characteristics | warehouse ventilation and low temperature drying |
| fire extinguishing agent | dry powder, foam, sand, carbon dioxide |
Last Update：2024-04-09 20:49:11
Supplier List
Multiple SpecificationsSpot supply
Product Name: Amoxapine Visit Supplier Webpage Request for quotationCAS: 14028-44-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Multiple SpecificationsSpot supply
Product Name: Amoxapine Visit Supplier Webpage Request for quotationCAS: 14028-44-5
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History